18:e201643068
The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisks semaglutide with Eli Lillys Trulicity (dulaglutide), already in the market, have revealed that Novos drug seems to be better at helping patients with type 2 diabetes control their blood sugar levels and reduce weight
CMS Issued Clarifying Guidance on Medicare GLP-1 Coverage for Cardiovascular Indications Following semaglutide's SELECT trial resultswhich demonstrated cardiovascular risk reduction in non-diabetic patients with obesitythe Centers for Medicare & Medicaid Services (CMS) issued updated guidance
Review other medications: Check for possible sedating effects or absorption issues caused by slower digestion
Always consult a healthcare provider to determine if its appropriate for your weight loss goals
Patients with hypertension should receive appropriate first-line antihypertensive therapy according to NICE hypertension guidelines (NG136), which recommend ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or thiazide-like diuretics as initial treatment depending on age, ethnicity, and comorbidities
